Update on Chemotherapy in the Treatment of Urothelial Carcinoma
Urothelial carcinoma is the fifth most common malignancy diagnosed each year in the United States. Neoadjuvant and adjuvant chemotherapy are given to decrease the risk of recurrent or metastatic disease with the more robust clinical data supporting the former. Bladder preservation utilizes a trimoda...
Saved in:
Main Authors: | Carrie Costantini, Frederick Millard |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2011-01-01
|
Series: | The Scientific World Journal |
Online Access: | http://dx.doi.org/10.1100/2011/590175 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Update on the Treatment of Metastatic Urothelial Carcinoma
by: Nedal Bukhari, et al.
Published: (2018-01-01) -
The Role of Chemotherapy in Upper Tract Urothelial Carcinoma
by: Peter H. O'Donnell, et al.
Published: (2009-01-01) -
Immunohistochemistry‐based molecular subtypes of urothelial carcinoma derive different survival benefit from platinum chemotherapy
by: Csilla Olah, et al.
Published: (2025-01-01) -
Nested Variant of Urothelial Carcinoma
by: Anthony Kodzo-Grey Venyo
Published: (2014-01-01) -
FAN score predicts prognosis after platinum-based first-line chemotherapy in patients with metastatic urothelial carcinoma
by: Yu Ishizuya, et al.
Published: (2025-02-01)